CARM

Carisma Therapeutics (CARM)

Carisma Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:CARM

1 2 3 4 5 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/06	00 : 45	Business Wire	CARMILA : Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiers	NASDAQ:CARM	Carisma Therapeutics Inc
2024/06/06	00 : 45	Business Wire	CARMILA: Information Concerning the Total Number of Voting Rights and Share	NASDAQ:CARM	Carisma Therapeutics Inc
2024/05/30	20 : 30	PR Newswire (US)	Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference	NASDAQ:CARM	Carisma Therapeutics Inc
2024/05/29	08 : 39	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:CARM	Carisma Therapeutics Inc
2024/05/16	20 : 30	PR Newswire (US)	Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte	NASDAQ:CARM	Carisma Therapeutics Inc
2024/05/09	20 : 52	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CARM	Carisma Therapeutics Inc
2024/05/09	20 : 41	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CARM	Carisma Therapeutics Inc
2024/05/09	20 : 30	PR Newswire (US)	Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights	NASDAQ:CARM	Carisma Therapeutics Inc
2024/05/09	00 : 45	Business Wire	Carmila: Withdrawal of funds for the liquidity contract	NASDAQ:CARM	Carisma Therapeutics Inc
2024/05/09	00 : 45	Business Wire	Carmila: Réduction des moyens du contrat de liquidité	NASDAQ:CARM	Carisma Therapeutics Inc
2024/05/08	20 : 30	PR Newswire (US)	Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024	NASDAQ:CARM	Carisma Therapeutics Inc
2024/05/08	00 : 45	Business Wire	CARMILA : Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiers	NASDAQ:CARM	Carisma Therapeutics Inc
2024/05/08	00 : 45	Business Wire	CARMILA: Information Concerning the Total Number of Voting Rights and Share	NASDAQ:CARM	Carisma Therapeutics Inc
2024/05/06	20 : 30	PR Newswire (US)	Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference	NASDAQ:CARM	Carisma Therapeutics Inc
2024/05/02	20 : 30	PR Newswire (US)	Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer	NASDAQ:CARM	Carisma Therapeutics Inc
2024/04/25	06 : 05	PR Newswire (US)	Carisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting	NASDAQ:CARM	Carisma Therapeutics Inc
2024/04/25	01 : 43	Business Wire	Carmila: Launch of a Share Buyback Program for €10 Million	NASDAQ:CARM	Carisma Therapeutics Inc
2024/04/25	01 : 43	Business Wire	Carmila : Lancement d’un programme de rachat d’actions pour 10 millions d’euros	NASDAQ:CARM	Carisma Therapeutics Inc
2024/04/23	05 : 35	PR Newswire (US)	Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting	NASDAQ:CARM	Carisma Therapeutics Inc
2024/04/18	00 : 45	Business Wire	Carmila : Information financière au 31 mars 2024	NASDAQ:CARM	Carisma Therapeutics Inc
2024/04/18	00 : 45	Business Wire	Carmila: First-quarter 2024 Financial Information	NASDAQ:CARM	Carisma Therapeutics Inc
2024/04/06	00 : 45	Business Wire	Carmila: Information Concerning the Total Number of Voting Rights and Share, Provided Pursuant to Article L.233-8 II of the Code de commerce (French Commercial Code) and Article 223-16 of the Règlement général de l’Autorité des marchés financiers	NASDAQ:CARM	Carisma Therapeutics Inc
2024/04/06	00 : 45	Business Wire	Carmila : Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiers	NASDAQ:CARM	Carisma Therapeutics Inc
2024/04/03	20 : 00	PR Newswire (US)	Carisma Therapeutics to Present at Upcoming Conferences	NASDAQ:CARM	Carisma Therapeutics Inc
2024/04/01	21 : 35	PR Newswire (US)	Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:CARM	Carisma Therapeutics Inc
2024/04/01	20 : 00	PR Newswire (US)	Carisma Therapeutics Announces Changes to its Board of Directors	NASDAQ:CARM	Carisma Therapeutics Inc
2024/03/22	06 : 00	PR Newswire (US)	Carisma Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting	NASDAQ:CARM	Carisma Therapeutics Inc
2024/03/16	01 : 45	Business Wire	CARMILA : INFORMATION RELATIVE A LA REMUNERATION DES DIRIGEANTS MANDATAIRES SOCIAUX	NASDAQ:CARM	Carisma Therapeutics Inc
2024/03/16	01 : 45	Business Wire	Carmila: Information Relating to Executive Corporate Officer Compensation	NASDAQ:CARM	Carisma Therapeutics Inc
2024/03/16	01 : 45	Business Wire	Carmila : Communiqué de mise à disposition du Document d’enregistrement universel 2023	NASDAQ:CARM	Carisma Therapeutics Inc